Luitpold Pharmaceuticals, Inc.
Ravi Tayi, MD, MPH., is Vice President and Chief Medical Officer at American Regent, Inc., a Daiichi Sankyo Group Company. As an executive, he leads American Regent teams with responsibilities for global drug development, drug safety and surveillance, medical affairs and quantitative sciences.
Dr. Tayi, has over 20 years of diverse experience, including US and global pharmaceuticals industry experience in direct and matrix organizations with knowledge and expertise across all functions within research and development, global medical affairs, and portfolio management.
Prior to joining American Regent, Dr. Tayi has held a variety of lead senior medical officer positions at Endo Pharmaceuticals, Ferring Pharmaceuticals, Mallinckrodt Pharmaceuticals/Ikaria, Optimer Pharmaceuticals/Cubist, Archimedes Pharma, Merck and Schering Plough. His experience spans across medical therapeutics, gene therapies, vaccines, sterile injectables, diagnostics, medical devices and generics across multiple therapeutic areas.
Dr. Tayi completed his medical degree at UFHEC, Dominican Republic, his residency and fellowship at Baylor - Scott and White in Temple, Texas and his Master of Public Health at Texas A&M University.
This person is not in any teams
This person is not in any offices
Luitpold Pharmaceuticals, Inc.
1 followers
Luitpold Pharmaceuticals, Inc., a Daiichi Sankyo Group Company, has a long history of quietly pioneering the development, manufacturing and marketing of a wide variety of drugs and medical devices. Each of our divisions — American Regent, Luitpold Animal Health, Osteohealth and PharmaForce — offer innovative solutions to our customers across the United States and Canada.